Heart Failure in East Asia
Heart Failure in East Asia
复制标题
DOI：
10.2174/1573403x11309020004
复制
发表时间：
2013-01-01
影响因子：
1.9
通讯作者：
Banerjee, Amitava
中科院分区：
文献类型：
--
作者：
Guo, Yutao;Lip, Gregory Y. H.;Banerjee, Amitava
心力衰竭(HF)在东亚是疾病的主要负担，与死亡和发病率相关的风险很高。近几十年来，随着东亚地区社会和经济的发展，出血热的流行病学发生了变化。东亚地区的心力衰竭负担仍然严重，整个地区的心力衰竭患病率从1.3%到6.7%不等。在大多数东亚国家，作为病因，缺血性心脏病有所增加，瓣膜疾病有所减少。利尿剂是最常用的药物(51.0%-97%)，其次是肾素-血管紧张素系统(RAS)抑制剂(59%-77%)，血管紧张素转换酶抑制剂(ACEI)(32%-52%)，以及血管紧张素-2受体阻滞剂(ARB)(31%-44%)。近年来，β-受体阻滞剂的使用也在增加。在中国、台湾、新加坡、泰国和日本，心力衰竭的总死亡率从2%到9%不等。65岁、糖尿病、贫血、肾功能不全和心房颤动(房颤)与不良结局相关。仍然需要更多前瞻性的、针对地区的数据，特别是关于依普利酮和伊夫拉定等新药疗法的数据。
Heart failure (HF) carries a major burden of disease in East Asia, with high associated risk of mortality and morbidity. In recent decades, the epidemiology of HF has changed with social and economical development in East Asia. The burden of HF is still severe in East Asia.The prevalence of HF ranges from 1.3% to 6.7% throughout the region. As aetiological factors, ischaemic heart disease has increased and valvular disease reduced in most East Asian countries. Diuretics are the most commonly used drugs (51.0%-97%), followed by renin-angiotensin system (RAS) inhibitors (59%-77%), with angiotensin-converting enzyme inhibitors, ACEI, (32%-52%) and has angiotensin-2 receptor blockers, ARBs (31%-44%) in similar proportions. Beta-blocker use has also increased in recent years.Total mortality from HF ranges from 2% to 9% in China, Taiwan, Singapore, Thailand, and Japan. Age>65 years, diabetes mellitus, anaemia, renal dysfunction and atrial fibrillation (AF) are associated with adverse outcome. More prospective, region-specific data are still required, particularly regarding new drug therapies such as eplerenone and ivabradine.